U.S., July 9 -- ClinicalTrials.gov registry received information related to the study (NCT07690761) titled 'Rituximab+ Zanubrutinib for Patients With Hairy Cell Leukemia and Hairy Cell Variant' on June 25.
Brief Summary: investigators propose a phase II, open label-nonrandomized, single arm, multicenter study aiming to assess the safety and efficacy with the combination of Rituximab and Zanubrutinib in patients with HAIRY CELL LUKEMIA HCL, or HAIRY CELL LEUKEMIA VARIANT-HCLv.
Study Start Date: June 01
Study Type: INTERVENTIONAL
Condition:
Hairy Cell Leukemia
Hairy Cell Leukemia Variant
Intervention:
DRUG: Zanubrutinib
Patients will receive Zanubrutinib orally (PO) ) 160 mg twice daily OR 320 mg once daily on days 1-28. (However, if ...